We are excited to announce that Talem Therapeutics, a subsidiary of IPA (ImmunoPrecise Antibodies), and LiberaBio have entered into a collaborative, multi-target AI-driven antibody discovery agreement to jointly address intracellular targets. It is estimated 75% of disease-causing targets are located inside cells. We applaud the cutting-edge collaboration to accelerate the race to bring new options to patients with cancer.

More information: